References
Brook JD, McCurrach ME, Harley HG, et al.: Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992, 68:799–808.
Liquori CL, Ricker K, Moseley ML, et al.: Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864–867.
Adler CH, Caviness JN, Hentz JG, et al.: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 2003, 18:287–293.
Zifko UA, Rupp M, Schwarz S, et al.: Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002, 249:983–987.
Damian MS, Gerlach A, Schmidt F, et al.: Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001, 56:794–796.
MacDonald JR, Hill JD, Tarnopolsky MA: Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002, 59:1876–1880.
Talbot K, Stradling J, Crosby J, Hilton-Jones D: Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord 2003, 13:357–364.
Rights and permissions
About this article
Cite this article
Hirano, M. Modafinil decreases hypersomnolence and improves mood in patients with myotonic dystrophy. Curr Neurol Neurosci Rep 4, 49–50 (2004). https://doi.org/10.1007/s11910-004-0011-y
Issue Date:
DOI: https://doi.org/10.1007/s11910-004-0011-y